- Home
- MDGL vs LAZ Comparison
MDGL vs LAZ Comparison
Compare MDGL & LAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDGL
- LAZ
- Stock Information
- Founded
- MDGL 2011
- LAZ 1848
- Country
- MDGL United States
- LAZ United States
- Employees
- MDGL N/A
- LAZ N/A
- Industry
- MDGL Biotechnology: Pharmaceutical Preparations
- LAZ Investment Managers
- Sector
- MDGL Health Care
- LAZ Finance
- Exchange
- MDGL Nasdaq
- LAZ Nasdaq
- Market Cap
- MDGL 6.1B
- LAZ 5.1B
- IPO Year
- MDGL N/A
- LAZ 2005
- Fundamental
- Price
- MDGL $414.68
- LAZ $56.00
- Analyst Decision
- MDGL Strong Buy
- LAZ Hold
- Analyst Count
- MDGL 8
- LAZ 9
- Target Price
- MDGL $445.71
- LAZ $52.88
- AVG Volume (30 Days)
- MDGL 469.6K
- LAZ 882.6K
- Earning Date
- MDGL 08-05-2025
- LAZ 07-24-2025
- Dividend Yield
- MDGL N/A
- LAZ 3.76%
- EPS Growth
- MDGL N/A
- LAZ 80.92
- EPS
- MDGL N/A
- LAZ 2.90
- Revenue
- MDGL $515,547,000.00
- LAZ $3,061,171,000.00
- Revenue This Year
- MDGL $286.67
- LAZ $0.43
- Revenue Next Year
- MDGL $67.98
- LAZ $15.61
- P/E Ratio
- MDGL N/A
- LAZ $19.33
- Revenue Growth
- MDGL 3421.98
- LAZ 10.05
- 52 Week Low
- MDGL $200.63
- LAZ $31.97
- 52 Week High
- MDGL $419.99
- LAZ $61.14
- Technical
- Relative Strength Index (RSI)
- MDGL 77.54
- LAZ 64.22
- Support Level
- MDGL $351.32
- LAZ $52.26
- Resistance Level
- MDGL $393.76
- LAZ $54.18
- Average True Range (ATR)
- MDGL 17.32
- LAZ 1.34
- MACD
- MDGL 6.15
- LAZ 0.02
- Stochastic Oscillator
- MDGL 94.95
- LAZ 99.98
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.
About LAZ Lazard Inc.
Lazard Inc has a storied history that can be traced back to 1848. The company's revenue is fairly evenly split between financial advisory, such as acquisition and restructuring advisory, and asset management. The company's asset management business is primarily driven by equities (over 80% of assets under management), has an international focus, and targets institutional clients. By geography, the company earns approximately 60% of revenue in the Americas, 35% in EMEA, and 5% in Asia-Pacific. Lazard has offices across more than 20 countries and over 3,000 employees.